Enovis (NYSE:ENOV) Releases Quarterly Earnings Results, Beats Expectations By $0.11 EPS

Enovis (NYSE:ENOV) announced its quarterly earnings data on Thursday. The company reported $0.88 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.77 by $0.11, FiscalAI reports. Enovis had a negative net margin of 47.96% and a positive return on equity of 12.03%. The firm had revenue of $558.73 million during the quarter, compared to analysts’ expectations of $557.12 million. During the same period in the prior year, the company posted $0.75 earnings per share. The company’s revenue for the quarter was up 1.8% compared to the same quarter last year.

Here are the key takeaways from Enovis’ conference call:

• Enovis delivered 5% organic sales growth in Q3, led by 6% growth in Recon; P&R grew 3%. Adjusted EPS rose 17% to $0.88, while adjusted EBITDA margin expanded 120 basis points to 18.5%.
• The company raised its adjusted EBITDA outlook to $428 million–$438 million and adjusted EPS outlook to $3.58–$3.79, while maintaining expected organic growth of about 5%. It also reaffirmed its goal of greater than 25% free-cash-flow conversion in 2026.
• Management described markets as volatile, citing choppy U.S. hip and knee demand, challenging Western European conditions, and Middle East conflict that reduced total company growth by about 40 basis points. Inflation in raw materials, freight and distribution also pressured costs, partly offset by tariff refunds.
• Enovis expects to close its eCential Robotics acquisition by year-end and is investing in talent and technology ahead of integration. Management expects to bring a knee robot to market within two years, with shoulder to follow, and said customer feedback has been encouraging.
• The board authorized a $200 million share repurchase program, which management said it will use opportunistically while targeting leverage of 2.5–3.5 times. Net leverage was 2.9 times at quarter-end and is expected to rise about half a turn after the eCential deal closes.

Enovis Trading Down 5.1%

NYSE:ENOV traded down $1.46 on Friday, reaching $27.16. The company’s stock had a trading volume of 2,304,734 shares, compared to its average volume of 1,449,886. The stock has a 50 day moving average price of $19.91 and a 200 day moving average price of $23.09. The firm has a market cap of $1.57 billion, a price-to-earnings ratio of 6.16 and a beta of 1.31. Enovis has a 12-month low of $16.70 and a 12-month high of $32.41. The company has a quick ratio of 1.00, a current ratio of 1.98 and a debt-to-equity ratio of 0.84.

Key Stories Impacting Enovis

Here are the key news stories impacting Enovis this week:

• Positive Sentiment: Q3 adjusted earnings were $0.88 per share, beating estimates of about $0.77 and topping $0.75 a year earlier. Revenue of $558.7 million slightly exceeded forecasts and grew 1.8% year over year. Enovis Q3 2026 results
• Positive Sentiment: Enovis raised its 2026 EPS guidance to $3.58–$3.79, signaling improved earnings expectations. Guidance and repurchase announcement
• Positive Sentiment: The company authorized a $200 million share-repurchase program, which could support per-share results and signal confidence in its prospects. Share-buyback announcement
• Positive Sentiment: Wells Fargo raised its target to $37 and maintained an Overweight rating; Needham lifted its target to $38 and BTIG to $42, both with Buy ratings. Wells Fargo analyst rating
• Neutral Sentiment: Canaccord lowered its price target from $45 to $42 but kept a Buy rating. Reports also highlighted product innovation and market-share gains, though market volatility remains a factor. Product innovation and share gains

Insider Activity

In other news, CEO Damien Mcdonald bought 13,035 shares of the stock in a transaction that occurred on Friday, September 4th. The stock was bought at an average cost of $19.15 per share, for a total transaction of $249,620.25. Following the acquisition, the chief executive officer directly owned 247,077 shares of the company’s stock, valued at $4,731,524.55. The trade was a 5.57% increase in their position. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Oliver Engert purchased 5,140 shares of the firm’s stock in a transaction on Thursday, September 3rd. The stock was acquired at an average cost of $19.46 per share, with a total value of $100,024.40. Following the transaction, the insider directly owned 61,238 shares in the company, valued at $1,191,691.48. This trade represents a 9.16% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders have purchased 23,293 shares of company stock worth $449,599. 2.90% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

ENOV has been the subject of a number of research reports. Canaccord Genuity Group dropped their price target on Enovis from $45.00 to $42.00 and set a “buy” rating for the company in a research note on Friday. Weiss Ratings raised Enovis from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday. UBS Group reaffirmed a “buy” rating and set a $44.00 price target on shares of Enovis in a research report on Monday, October 5th. BTIG Research upped their target price on Enovis from $36.00 to $42.00 and gave the stock a “buy” rating in a research note on Thursday. Finally, Needham & Company LLC raised their price objective on Enovis from $34.00 to $38.00 and gave the company a “buy” rating in a report on Thursday. Ten research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $38.62.

About Enovis

Enovis Corporation (NYSE: ENOV) is a medical technology company that develops, manufactures and distributes products designed to improve patient recovery, mobility and quality of life. Its portfolio serves orthopedic, sports medicine, physical therapy and rehabilitation markets, as well as other areas of musculoskeletal care.

The company’s products include orthopedic implants and surgical technologies, braces and supports, cold and compression therapy systems, electrotherapy and rehabilitation equipment, and other solutions used by hospitals, surgeons, physical therapists, athletic trainers and patients.